Full Press Release Details
ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
Fla., February 26, 2025/ AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced
that it received notice from the NYSE American (the "American") that the American has accepted the Company's Plan to
regain compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the American Company
Guide. AIM has until June 11, 2026 to regain compliance with the NYSE's Continued Listings Standards.
CEO Thomas K. Equels stated: "We are pleased that the NYSE American has approved our plan and look forward to executing the strategy
over the coming months as we also continue to make advancements in our oncology and antiviral pipelines."
ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers,
immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called
Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials
for globally important cancers, viral diseases and disorders of the immune system.
more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
current report, including exhibit 99.1, contains forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 (the "PSLRA"). Words such as "may," "will," "expect," "plan,"
"anticipate," "continue," "believe," "potential," "upcoming" and other variations
thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify
forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. There can be no assurance
that the Company will be able to achieve compliance with the American's continued listing standards within the required timeframe.
The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors
or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You
are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this current report.
Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained
in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that
occur after the date hereof.